<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00210314</url>
  </required_header>
  <id_info>
    <org_study_id>IELSG20</org_study_id>
    <nct_id>NCT00210314</nct_id>
  </id_info>
  <brief_title>Phase II Trial of Combined Modality Treatment in Primary Central Nervous System Lymphoma</brief_title>
  <official_title>Randomized Phase II Trial on Primary Chemotherapy With High-dose Methotrexate, Alone or Associated With High-dose Cytarabine, Followed by Response- and Age-tailored Radiotherapy for Immunocompetent Patients With Newly Diagnosed Primary Central Nervous System Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International Extranodal Lymphoma Study Group (IELSG)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>International Extranodal Lymphoma Study Group (IELSG)</source>
  <brief_summary>
    <textblock>
      Aim of the study is to establish in a prospective, randomized clinical trial the activity of
      primary chemotherapy containing high dose-methotrexate, alone or combined with high dose
      cytarabine, in patients with primary central nervous system lymphoma
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2003</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The main endpoint is the complete remission (CR) rate after chemotherapy</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response duration (time to relapse or progression) for responder patients</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Meningeal relapse rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early and late neurotoxicity</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">79</enrollment>
  <condition>Lymphoma, B Cell</condition>
  <arm_group>
    <arm_group_label>High-dose methotrexate alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>High-dose methotrexate associated with high dose cytarabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>high dose methotrexate</intervention_name>
    <arm_group_label>High-dose methotrexate alone</arm_group_label>
    <arm_group_label>High-dose methotrexate associated with high dose cytarabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>high dose cytarabine</intervention_name>
    <arm_group_label>High-dose methotrexate associated with high dose cytarabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiotherapy</intervention_name>
    <arm_group_label>High-dose methotrexate alone</arm_group_label>
    <arm_group_label>High-dose methotrexate associated with high dose cytarabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histological or cytological diagnosis of non-Hodgkin's lymphoma.

          2. Diagnostic sample obtained by stereotactic or surgical biopsy, CSF cytology
             examination or vitrectomy.

          3. Disease exclusively localized into the central nervous system, cranial nerves or eyes.

          4. Untreated patients (patients treated with steroids alone are eligible).

          5. At least one measurable lesion.

          6. Age 18 - 75 years.

          7. ECOG performance status &lt; 3

          8. HBsAg-negative and Ab anti-HCV-negative serologic status.

          9. No known HIV disease or immunodeficiency.

         10. Adequate bone marrow (PLT &gt; 100000 mm3, Hb ≥ 9 g/dl, ANC ≥ 2.000 mm3), renal
             (creatinine clearance ≥ 60 mL/min), cardiac (VEF ≥ 50%), and hepatic function (total
             serum bilirubin &lt; 3 mg/dL, AST/ALT and gGT &lt; 2 per upper normal limit value).

         11. No previous or concurrent malignancies with the exception of surgically cured cervical
             intraepithelial neoplasia type 1 (CIN1) or localized non-melanomatous skin cancer and
             of other cancers without evidence of disease since at least 5 years (patients with a
             previous lymphoma diagnosis will be excluded).

         12. Absence of any familial, sociological or geographical condition potentially hampering
             compliance with the study protocol and follow-up schedule.

         13. Non-pregnant and non-lactating status for female patients. Adequate contraceptive
             measures during study participation for sexually active patients of childbearing
             potential.

         14. No concurrent treatment with other experimental drugs.

         15. Informed consent signed by the patient before registration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andres JM Ferreri, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Radiochemotherapy. San Raffaele Hospital. Milan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michele Reni, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Radiochemotherapy. San Raffaele Hospital. Milan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Emanuele Zucca, MD</last_name>
    <role>Study Chair</role>
    <affiliation>International Extranodal Lymphoma Study Group/Oncology Institute of Southern Switzerland (IOSI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oncology Institute of Southern Switzerland (IOSI)</name>
      <address>
        <city>Bellinzona</city>
        <zip>6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>http://www.ielsg.org</url>
    <description>Click here for more information about this study</description>
  </link>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <last_update_submitted>March 27, 2015</last_update_submitted>
  <last_update_submitted_qc>March 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 30, 2015</last_update_posted>
  <responsible_party>
    <name_title>International Extranodal Lymphoma Study Group (IELSG)</name_title>
    <organization>IELSG</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

